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EXPERIMENTAL STUDIES
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in a Myocardial Infarction Model in
the Rat—Angiogenesis and Angioma Formation
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Jeffrey M. Isner, MD,‡ Laurence H. Kedes, MD,§ Robert A. Kloner, MD, PHD*†
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OBJECTIVES The effects of direct intramyocardial injection of the plasmid encoding vascular endothelial
growth factor (phVEGF165) in the border zone of myocardial infarct tissue in rat hearts were
investigated.
BACKGROUND Controversy exists concerning the ability of VEGF to induce angiogenesis and enhance
coronary flow in the myocardium.
METHODS Sprague-Dawley rats received a ligation of the left coronary artery to induce myocardial
infarction (MI). At 33.1 6 6.5 days, the rats were injected with phVEGF165 at one location
and control plasmid at a second location (500 mg DNA, n 5 24) or saline (n 5 16). After
33.1 6 5.7 days, the hearts were excised for macroscopic and histologic analysis. Regional
blood flow ratios were measured in 18 rats by radioactive microspheres.
RESULTS phVEGF165-treated sites showed macroscopic angioma-like structures at the injection site
while control DNA and saline injection sites did not. By histology, 21/24 phVEGF165-
treated hearts showed increased focal epicardial blood vessel density and angioma-like
formation. Quantitative morphometric evaluation in 20 phVEGF165-treated hearts revealed
44.4 6 10.5 vascular structures per field in phVEGF165-treated hearts versus 21.4 6 4.7 in
control DNA injection sites (p , 0.05). Regional myocardial blood flow ratios between the
injection site and noninfarcted area did not demonstrate any difference between phVEGF165-
treated hearts (0.9 6 0.2) and saline-treated hearts (0.7 6 0.1).
CONCLUSIONS Injection of DNA for VEGF in the border zone of MI in rat hearts induced angiogenesis.
Angioma formation at the injection sites did not appear to contribute to regional myocardial
blood flow, which may be a limitation of gene therapy for this application. (J Am Coll
Cardiol 2000;35:1323–30) © 2000 by the American College of Cardiology
Severe and prolonged ischemia results in cell death. Al-
though ischemia is thought to be a stimulus for angiogenesis
via vascular growth factors (1,2) (i.e., the production and
development of new blood vessels to provide ischemic tissue
with oxygen), the production for new vascular cells requires
approximately 24 h (2), a time frame during which irrevers-
ible cardiomyocyte death has already occurred. One of the
major challenges of cardiovascular research is to reduce the
impact of myocardial ischemia by means of thrombolytic or
interventional therapy shortly after acute coronary occlusion
or by enhancing angiogenesis in the setting of chronic
ischemia (3). Recent advances in molecular biology have
allowed for the introduction of deoxyribonucleic acid
(DNA) encoding angiogenic proteins into tissues, and this
has been shown to augment collateralization (4–6). Gene
therapy with vascular endothelial growth factor (VEGF), a
45-kD heparin-binding dimeric glycoprotein that is an
endothelial cell specific mitogen (7–9), has been shown to
be effective in hind limb ischemia models in the rabbit
(10–12) and demonstrated striking effects in a single patient
with claudication (13). Its effects in the heart are contro-
versial (14,15).
From the *Heart Institute Research, Good Samaritan Hospital and †Division of
Cardiology, University of Southern California, Los Angeles, California; and the
‡Division of Cardiovascular Research, St. Elisabeth’s Medical Center and Tufts
University School of Medicine, Boston, Massachusetts; and the §Department of
Biochemistry and Molecular Biology, Department of Medicine, University of South-
ern California, Los Angeles, California. Supported in part by the Kenneth T. and
Eileen L. Norris Foundation.
Manuscript received February 4, 1999; revised manuscript received November 5,
1999, accepted December 15, 1999.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00522-2
An elegant series of experiments defined striated muscle
(16–19), including heart (20–22) as a tissue with the unique
property of being able to take up and express recombinant
proteins after local injection of DNA. Such direct injection
technology is capable of delivering exogenous genes into
myocardium fully governed by hormone inducible, tissue
specific or strong viral promoters (23–25). We hypothesized
that ischemic myocardium would be capable of taking up
and expressing VEGF delivered by plasmid DNA injec-
tions. So far, the effects of VEGF in infarcted tissue in the
rat heart have not been investigated. We hypothesized that
application of VEGF encoding DNA directly to the healing
infarct might augment angiogenesis and increase blood flow
in infarcted rat heart. Potential benefits would include
enhancing blood flow to a healing infarct, possibly acceler-
ating healing, preventing remodeling and allowing open
vessels to provide drugs to the area of scar. In addition,
clinical trials are currently underway assessing the effect of
this type of gene therapy in patients with chronic ischemia.
Whether injection of the gene for VEGF into tissue
recently infarcted is safe is not yet known.
METHODS
Preparation of plasmid DNA. The plasmids phVEGF165
or pCMVbeta (Clontech Laboratories, Palo Alto, Califor-
nia) were transformed into DH5a cells (Gibco Max Effi-
ciency competent cells), plated on LB plates containing
ampicillin (100 mg/ml) and grown overnight at 37°C. Single
colonies were picked into 10 ml of LB plus ampicillin and
grown for 8 to 10 h at 37°C. Aliquots of 5 ml were used to
inoculate 1L of prewarmed LB plus ampicillin, and the
culture was incubated overnight with shaking.
DNA was extracted from the cultures with Qiagen
Plasmid Giga Kit. Three L of culture usually provided 10 to
12 mg of plasmid DNA. All experiments were conducted in
accordance with institutional guidelines and The Guide for
the Care and Use of Laboratory Animals published by the
National Research Council, Washington DC, 1996.
Sprague-Dawley rats, weighing between 200 and 350 g,
were used (Charles River, Inc., Wilmington, Massachu-
setts). Each rat underwent:
1) at baseline, coronary occlusion;
2) at a mean of 33.1 6 6.5 days, range of 24 to 50 days,
injections at two separate sites of phVEGF165 and
control DNA or saline; and
3) at a mean of 33.1 6 5.1 days, range of 26 to 44 days,
excision of the hearts.
Apart from the final procedure, all surgeries were performed
under aseptic conditions. The rats were anesthetized with
ketamine (75 mg/kg) and xylazine (5 mg/kg), intraperito-
neally. They were intubated and artificially respirated with a
rodent respirator (Harvard) with 15 to 20 ml/kg room air at
a respiration rate of 75 breaths/min.
Coronary artery occlusion. The chest was opened in the
fourth intercostal space. The pericardium was opened, and a
6.0 prolene suture was placed around the base of the left
coronary artery near the left atrial appendage. Coronary
occlusion was confirmed by the presence of deep S waves on
the electrocardiogram (ECG) and ventricular arrhythmias
within the first 20 to 30 min after occlusion. Thereafter, the
chest and the skin were closed in layers, and the animals
were allowed to recover.
Injection of phVEGF165 or saline. At 33.1 6 6.5 days
after coronary artery occlusion, the animals were used for
either a treated (phVEGF165) group or a control (saline)
group in random order (except the first five animals, which
all received phVEGF165). The feasibility of gene transfer in
the rat model has been described before by our group
(25–27). This time interval after coronary occlusion was
chosen to avoid injection into necrotic debris but chosen to
inject into partially healed infarcts. After opening the chest
and identifying the infarcted area in the anterolateral wall,
two 6.0 prolene sutures were placed at the border zones of
the infarcted tissue: one anteriorly and one laterally. These
areas were chosen for two reasons: 1) to introduce plasmid
DNA into a “watershed” area in terms of blood supply, and
2) to augment the effects of locally expressed VEGF from
cells bordering the necrotic area (19,20). The sutures were
used to stabilize the myocardium for injection and to close
the injection hole so that the agents would not leak out. In
the treated group, 500 mg of phVEGF165 plasmid DNA in
a volume of 0.15 ml was injected intramyocardially at the
left anterior border zone of the visible scar tissue in the left
anterior free wall by use of a 0.5 ml syringe and a 24G
needle. In the same rats, control DNA (500 mg, 0.15 ml) of
the reporter gene pCMVbeta (7.2 Kb), a plasmid capable of
expressing the E. coli beta-galactosidase gene under the
control of human cytomegalovirus (CMV) immediate early
promoter/enhancer was injected into the left lateral border
zone of the scar tissue. Thirty-six animals were used for the
phVEGF165 group, and 19 animals were used for saline-
treated controls (that is, without DNA injection). In a
subgroup of eight animals, the injection sites for ph-
VEGF165 and pCMVbeta were changed to the lateral and
anterior infarct border zones, respectively. In control ani-
mals, 0.15 ml saline was injected at both sites. Care was
taken to inject the substances within the epicardial layer of
the scar, and this was confirmed by the presence of a ‘bubble’
in the epicardium as the syringe was unloaded. In two
Abbreviations and Acronyms
CMV 5 cytomegalovirus
DNA 5 deoxyribonucleic acid
ECG 5 electrocardiogram
H 1 E 5 hematoxylin and eosin
MI 5 myocardial infarction
VEGF 5 vascular endothelial growth factor
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animals (one from each group), the sutures were removed a
few minutes after injection to assess the effects of the suture
material. Thereafter, the chest was closed and the animals
were allowed to recover.
Expression of VEGF. To ensure that the phVEGF165
plasmid expresses VEGF, an in vitro analysis using mam-
malian cells was performed. Therefore, 293 and cos 7 cells
were transfected with plasmid DNA using the calcium
phosphate precipitation method. After 72 hours, the media
was harvested and washed cells lysed. The media was
concentrated ten-fold with 75% ammonium sulfate. Ali-
quots of boiled media and lysate were separated by dena-
turing polyacrylamide gel electrophoresis and examined by
Western blotting with A-20, an anti-VEGF antibody
(Santa Cruz Biotechnology) and antirabbit IgG (Amer-
sham, Sunnyvale, California). Furthermore, VEGF protein
and aliquots of media and cell lysate from cells transfected
with the plasmid vector backbone were examined.
Radioactive microsphere injection and excision of the
hearts. 33.1 6 5.7 days after injection, all animals were
reanesthetized, and the chest was opened. In a subgroup of
18 animals, radioactive microspheres (NEN Research Prod-
ucts, Boston, Massachusetts), approximately 100,000 in
number, labeled with 141Ce, were injected into the left
ventricular cavity. The microspheres were allowed to circu-
late for one min. Thereafter, the animals were euthanized,
and the hearts were excised. Tissue specimens from the
anterior and the lateral injection sites within the infarcted
border zone and from the septum were excised for measure-
ments of radioactivity. All infarcts were fairly large, and they
were composed of mainly fibroblasts and collagen. The
activities in the VEGF-injected and the saline-injected
regions were expressed per weight of heart tissue as a ratio
relative to the activity in the septum and the control
infarcted tissue.
Morphologic analysis. After excision of the hearts at
33.1 6 5.7 days after injection, the injection sites were
identified and examined grossly in all hearts. Short axis
slices were made from apex to base. In hearts that did not
receive microspheres, the transmural slices were then pro-
cessed for histology. In hearts used for radioactive micro-
sphere injection, hearts were dissected, and the samples used
for radioactivity measurements were examined for later
histologic analysis. The slices were processed for
hematoxylin-eosin (n 5 39) and smooth muscle alpha-actin
antibody staining (n 5 20), as previously reported (28).
In addition, tissues from four VEGF-treated hearts
and one control heart were incubated with antihuman
antibody to VEGF (R&D Systems, Minneapolis, Minne-
sota) at a concentration of 50 mg/ml for 20 min at 37°C, in
humidity chambers. After rinsing in PBS, the tissues were
incubated in horse radish peroxidase–tagged labeling re-
agent (BioGenex, San Ramon, California) for an additional
20 min at 37°C. The specimens were rinsed in PBS and
reacted with metal enhanced diaminobenzidine (Sigma) for
2 to 5 min at room temperature, with periodic monitoring
by microscopic examination. After development, the sam-
ples were rinsed and stained with either hematoxylin and
eosin or nuclear fast red and metanil yellow. Sections were
dehydrated through xylene and mounted with permount.
In a subgroup of 30 animals, a morphometric analysis of
blood vessels was conducted. The hematoxylin and eosin
(H 1 E) slides were examined and marked by one investi-
gator on each side of the infarction. This corresponded to
the injection sites of phVEGF165 or pCMVbeta or saline
(or noninjection). The slides were then examined for evi-
dence of vascular proliferation by another investigator un-
aware of the treatment groups. The tissue sections were
projected through a 103 objective and a 43 projection lens
to a 46 3 61 cm paper palate and the tissue perimeter and
vascular structures identified, outlined and planimetered.
In a subgroup of animals, the epicardial and endocardial
circumferences of the infarcted ventricle (scar) and the total
left ventricle were measured by planimetry and expressed as
the ratio of scar circumference to left ventricular circumfer-
ence.
Statistical analysis. All values are given as means 6
standard error of the mean (SEM). Comparisons between
the groups or within the groups were made using paired or
group t test, as appropriate. Data regarding histology of the
angiomatous structures were tested by Fisher exact test. P
values ,0.05 were considered statistically significant.
RESULTS
A total of 56 rats that survived the coronary occlusion proce-
dure were used for either the treatment (phVEGF165) or
control (saline) group. One rat died during anesthesia before
injection, 15 rats (27%) died within 24 h after the surgery (12
rats after injection of phVEGF165, 3 rats after injection of
saline). Forty surviving rats (24 phVEGF165-treated rats, 16
control rats) were analyzed.
Macroscopic evaluation (Figure 1, A and B). Macro-
scopic inspection of the hearts at the time of euthanasia
typically revealed the presence of broad-based angioma-like
formations at the site of phVEGF165 injection, whether
injected anteriorly or laterally, but not at the site of
pCMVbeta injection. The angioma-like structure was also
found in the heart in which the suture material was removed
after injection. In contrast, saline injected control hearts
demonstrated small adhesions in some cases but no
angioma-like structures.
Qualitative histologic analysis. Light microscopy of the
H 1 E slices was performed in 24 phVEGF165-treated
hearts and in 15 saline-treated control hearts. Angioma-like
structures, which appeared to be vascularized formations
originating from a broad base upon the epicardial surface,
were found in 21/24 phVEGF165-treated hearts. In one of
the control hearts, there was increased vascularity in the
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region of the saline injection site with minimal protuberance
over the scar (p , 0.0001, Fisher exact test).
Cross sections of H 1 E slices of phVEGF165-treated
hearts containing these angioma-like structures showed
them protruding from the surface of the scars often several
mm. Within these structures most of the small vessels
consisted only of simple endothelial cell tubes, but some
vessels with smooth muscle cells in the media also were
identified. Erythrocytes often could be visualized within the
vessels. Lymphocytes were occasionally found in treated and
control hearts at the injection sites and tended to be more
prominent in hearts injected with phVEGF165. Both com-
pact and loose fibrous tissue were also visualized in these
structures as well as occasional fat cells. Figures 2 and 3
illustrate typical H 1 E examples for phVEGF165-treated
and control hearts. Within the angiomatous structures,
most vascular structures were negative for alpha-actin stain-
ing, again suggesting that they were primarily simple endo-
thelial tubes without smooth muscle.
Staining for VEGF in a subgroup of VEGF-treated
hearts demonstrated brownish-black positive stain, which
was observed to be concentrated around angiomatous struc-
tures. The cells that appeared to express VEGF were most
likely fibroblasts.
Morphometric analysis of vascular structures. Morpho-
metric analysis was performed in 20 phVEGF165-treated
hearts and in 10 saline-treated control hearts. In
phVEGF165-treated hearts, the slices containing angioma-
like structures were analyzed. In addition, in five
phVEGF165-treated hearts, slices that did not contain the
angioma-like structures were also analyzed. The number of
vascular structures within the projected field was signifi-
cantly higher in phVEGF165-injected sites at 44.4 6 10.5
per field as compared with pCMVbeta-injected areas at
21.4 6 4.7, p , 0.05, and significantly higher compared
with the equivalent saline injection sites in control animals
(21.1 6 3.0, p , 0.05 vs. phVEGF165 injection site). There
was a nonsignificant trend toward higher numbers of
vascular structures in phVEGF165 injection sites if com-
pared with all saline injection sites in control animals
(30.1 6 4.6). In contrast, in those slices not containing
angioma-like structures in the phVEGF165-treated hearts,
there were 12.6 6 2.2 vascular structures (p , 0.05 vs.
phVEGF165-treated slices with angioma-like structures
[44.4 6 10.5]). The percent of the area examined that
contained vascular structures was greater within those left
ventricular slices containing angioma-like structures in
phVEGF165-treated animals (4.5 6 1.3%) versus those
slices in phVEGF165-treated animals that received control
DNA (1.1 6 0.1%, p , 0.05) versus equivalent control
saline-treated areas (2.4 6 0.6, p 5 0.08) versus all saline
injected areas (2.8 6 0.6%).
Expression of VEGF. We insured that phVEGF165 was
capable of producing VEGF polypeptide in mammalian
cells. Bands at 21 kD corresponding to the reported size of
phVEGF165 were present in both cell lysate and media of
both 293 and cos 7 cells. To insure further that the bands
were not due to interaction between VEGF and secondary
antibody, primary antibody was neutralized by a blocking
peptide (Santa Cruz Biotechnology, Santa Cruz, California)
before incubation with the membrane. The 21 kD bands
and the positive control band were no longer detected.
Thus, mammalian cells carrying the phVEGF165 plasmid
DNA we delivered to the myocardium was capable of
synthesizing and secreting VEGF protein.
Measurement of infarct and left ventricular circumfer-
ences. Measurements of the epicardial and endocardial
infarct scar and total circumferences of the left ventricle in
22 hearts (12 phVEGF165-treated hearts and 10 controls)
revealed an epicardial scar/left ventricular circumference
ratio of 0.26 6 0.02 in phVEGF165-treated animals versus
0.32 6 0.03 in controls (p 5 0.09). The endocardial
scar/left ventricular circumference ratio was 0.34 6 0.04 in
Figure 1. (A) Rat heart with infarct (white scar) four weeks after
injection of plasmid for phVEGF165. Note prominent red angio-
matous structure on the anterior surface of the scar (arrow). (B)
Rat heart with infarct four weeks after injection of saline. A few
threadlike adhesions are present near site of saline injection (two
lower sutures) but no angioma.
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VEGF-treated hearts versus 0.40 6 0.04 in controls (p 5
NS).
Measurements of regional blood flow. Radioactive micro-
spheres were used to measure relative blood flow in 12
phVEGF165-treated hearts and in six saline-treated con-
trols. The septum, which was noninfarcted in this model,
served as the reference region. The pCMVbeta injection site
served as the control infarct region in treated animals. The
ratios between phVEGF165 injection site and pCMVbeta
injection site in treated and between the two saline injection
sites in control animals were used for group comparison.
The ratio of counts of the injection site and in the septum
between treated and control hearts were analyzed (Table 1).
There were no significant differences in relative blood flow
between the two groups.
DISCUSSION
This is the first study investigating the effects of direct
phVEGF165 plasmid DNA injection in myocardial infarct
tissue in the rat heart. The main findings are: 1)
Figure 2. (A) Hematoxylin-eosin staining of cross section of rat infarct scar from a control heart after eight weeks. Most of the anterior
free wall is replaced with fibrous tissue. There are a few islands of viable myocytes in the subepicardium and around vessels in the
subepicardium. The LV cavity is at the lower left. (B) phVEGF165 treated scar. The infarct is at the lower left (same orientation as ([A]).
There is a broad-based mass protruding from the surface of the scar that contains numerous vascular structures as well as fibrous tissue.
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phVEGF165 injection caused angiogenesis, i.e., new vessel
formation at the injection site compared with pCMVbeta or
saline injection or noninjected tissue; 2) new vessels were
located within angioma-like formations, i.e., richly vascular
structures protruding from the surface of the heart; and 3)
there was no difference in relative regional myocardial blood
flow between the phVEGF165-treated and the control
groups; that is, the angiomatous structures did not contrib-
ute to improved regional flow within the myocardium.
These data are primarily observational but might be impor-
tant for future use of vascular growth factors.
The development of angiomatous structures. The devel-
opment of angioma-like structures was found only within
the phVEGF165-injected areas and was independent of its
location or the presence of a suture. The development of
these angioma-like structures is probably analogous to the
role of VEGF in tumor angiogenesis (29,30). The clinical
significance of these angiomas over time remains unknown.
They did not worsen infarct expansion, and, in fact, there
was a nonsignificant trend to reduce scar circumference in
phVEGF165-treated hearts.
It has been shown in dogs that infarcted or chronically
ischemic myocardial tissue is more sensitive to the mito-
genic effects of another growth factor—exogenous acidic
fibroblast growth factor—because its epicardial application
induced a tumor-like smooth muscle cell hyperplasia (31).
In our study, tumor-like angioma occurred within infarcted
tissue; this phenomenon might limit the clinical application
of VEGF by plasmid DNA injection in the treatment of
myocardial ischemia in human patients and suggests that
such injection perhaps should be avoided in patients with
recent infarcts. Of note, one patient who received the
plasmid for VEGF in the peripheral arteries developed
transient cutaneous angiomas (13). A recently published
report of direct injection of phVEGF165 into human myo-
cardium in five patients demonstrated a slight reduction of
symptoms and improvement in myocardial perfusion (as
assessed by nuclear imaging [32]). However, a macroscopic
or histologic evaluation of the injection sites was not
feasible, and a clinical follow-up is not yet available, but
these patients had no recent myocardial infarction, which
might play a role in the development of angiomatous
structures.
The effects on myocardial perfusion. Relative, rather than
absolute, blood flow measurements were performed in our
model because of the difficulty of withdrawing reference
blood samples in the rat. The phVEGF165 injection site/
control area ratios did not show any significant difference
compared with controls. Potential explanations for this
include the possibility that the new blood vessels were
simply too small to allow microsphere penetration, that the
spheres may have shunted around the blood vessels in the
angioma or that the possibility that flow within these
angiomatous structures simply does not differ from flow in
the control border zone—that is, these structures may not
Figure 3. Various sized new blood vessels within angiomatous structure of phVEGF165-treated animal. The cells are primarily composed
of a few endothelial cells forming a ring.
Table 1. Regional Blood Flow Ratios
Group I (VEGF) n 5 12 VEGF inj./contr. inf. 1.5 6 0.5
Group II (saline) n 5 6 saline inj./contr. inf. 1.4 6 0.4
Group I (VEGF) n 5 12 VEGF inj./septum 0.9 6 0.2
Group II (saline) n 5 6 saline inj./septum 0.7 6 0.1
contr. 5 control injection site; inf. 5 infarct; inj. 5 injection site.
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contribute to overall increase in regional myocardial blood
flow.
A variety of studies have investigated the effects of VEGF
to induce angiogenesis in peripheral arteries of animals
(10–12,27,33,34) and, recently, humans (13,35–37), with
some degree of success. Furthermore, in dogs subjected to
chronic left circumflex artery stenosis, intracoronary admin-
istration of VEGF-peptide increased collateral blood flow
(14). In contrast, in another study in dogs subjected to
chronic left circumflex artery occlusion, VEGF-protein
injected into the left atrial cavity had no effect on collateral
flow or blood vessel development (while basic fibroblast
growth factor did) (15). The differences between this and
the other studies might be explained by the difference in the
models, species, route of protein delivery or severity of the
ischemic stimulus.
Preliminary results are available from intracoronary ap-
plication of VEGF-protein in the human heart, which
demonstrates improvement in myocardial perfusion as as-
sessed by nuclear imaging (38). However, it remains to be
seen whether application of VEGF has long-term beneficial
effects in the heart. Notably, it has not been shown whether
angiogenesis augments contractile function. In the setting of
a healed myocardial infarction, if angiogenesis is induced, it
may either improve perfusion of scar tissue or border zone
tissue, or, alternatively, the gene and its effect may be
distributed all over the heart (“A little VEGF goes a long
way,” [39]) with improvement in perfusion and salvage of
jeopardized cells (40,41). The beneficial effects of VEGF-
induced angiogenesis may be masked by the induction of
vascular abnormalities, which have been described recently
after intravitreous injection in monkeys (42). Furthermore,
it has been shown that expression of VEGF is not only
essential for embryonic angiogenesis but also can induce the
formation of angioblasts, hemangioblasts and vascular and
cardiovascular malformation (43,44). This is not surprising
given the involvement of VEGF in tumorgenesis (29,30)
and neonatal hemangiomas (45).
Study limitations. The exact reason that more rats died
within 24 h in the VEGF group is unknown, but:
1) more rats were used for phVEGF165 injection than for
saline, and
2) severe hypotension as a side-effect of VEGF in pigs
(46,47) and humans (38) has been reported.
One explanation for our findings might be that a high
transfection efficiency of gene expression caused angioma
formation in our study. The present data confirm that
injection of the plasmid causes expression of VEGF, and we
demonstrated that labeling appeared most intense around
the angioma, indicating an effect directly caused by VEGF
plasmid injection. However, we used a dose of phVEGF165
identical to that used in rabbits before. The much smaller
body weight of rats might have influenced the results.
Therefore, in a recent study, smaller doses of phVEGF165
were used (125 mg), similar to doses used in clinical trials,
and this did not result in gross angiomas in the rat model
(48). These findings support, in part, a dose-dependence
that previously has been reported after VEGF gene appli-
cation in muscle tissue (49). In that study, Spinger et al. (49)
reported that high levels of VEGF expression caused
hemangiomas in adult skeletal muscles, whereas muscle
exposed to low serum levels did not develop vascular
malformations.
Conclusions. It seems that a potential therapeutic appli-
cation of VEGF in a setting of myocardial ischemia or
infarction is a double-edged sword: on one hand it has the
ability to induce angiogenesis and enhance coronary flow
(50), while on the other hand it may also induce vascular
malformation. Whether the dose that was used here or the
location, mode or time of VEGF injection or other factors
play a role in the development of angiomas in our model has
not yet been clarified. There is a need for further experi-
mental studies using VEGF to identify the circumstances
under which collateral flow can be enhanced without devel-
opment of vascular malformations.
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